2m 2m 2m 2m 2m 2m 2m
Arbutus Biopharm (ABUS)
NASDAQ
$4.50-$0.02 (-0.55%)
Price as of Jun 23, 2026 7:26 PM EDT- $892.9MMarket Cap
- 32.55%1-Year Change
- BiotechnologyIndustry
Arbutus Biopharm (ABUS)
$4.50-$0.02 (-0.55%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 12.6M +221.54% | 3.9M -78.40% | 18.1M -53.51% | 39.0M +255.11% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 12.6M +221.54% | 3.9M -78.40% | 18.1M -53.51% | 39.0M +255.11% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -25.2M -53.29% | -54.0M -26.68% | -73.7M -12.69% | -84.4M +28.86% | |
Depreciation and Amortization Expense | 363,000 -73.70% | 1.4M -1.71% | 1.4M -1.61% | 1.4M -18.60% | |
Total Operating Expenses | 52.2M -36.67% | 82.5M -14.29% | 96.2M -7.88% | 104.5M +23.62% | |
Operating Profit | -38.2M -50.00% | -76.3M -2.28% | -78.1M +19.32% | -65.5M -10.97% | |
Interest Income | 4.1M -38.22% | 6.6M +15.77% | 5.7M +159.49% | 2.2M +1,625.98% | |
Interest Expense | N/A N/A | N/A N/A | -459,000 -73.41% | -1.7M -39.59% | |
Interest Income and Expense and Net | 4.1M -38.22% | 6.6M +25.93% | 5.2M +1,022.10% | 466,000 +117.07% | |
Total Nonoperating Income and Expense | 4.7M -27.19% | 6.4M +21.79% | 5.3M +1,083.33% | 444,000 +116.29% | |
Income before Taxes | -38.2M -45.42% | -69.9M -4.02% | -72.8M +12.05% | -65.0M -26.45% | |
Income Taxes | 0 N/A | 0 N/A | 0 -100.00% | 4.4M N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -33.5M -52.09% | -69.9M -4.02% | -72.8M +4.89% | -69.5M -8.91% | |
Net Income from Continuing Operations Applicable to Common | -33.5M -52.09% | -69.9M -4.02% | -72.8M +4.89% | -69.5M -21.42% | |
Basic EPS and Net Income | -0.17 -55.26% | -0.38 -13.64% | -0.44 -4.35% | -0.46 -44.58% | |
Diluted EPS and Net Income | -0.17 -55.26% | -0.38 -13.64% | -0.44 -4.35% | -0.46 -44.58% | |
Basic Weighted Average Shares | 191.6M +3.23% | 185.6M +11.84% | 166.0M +9.95% | 150.9M +42.07% | |
Diluted Weighted Average Shares | 191.6M +3.23% | 185.6M +11.84% | 166.0M +9.95% | 150.9M +42.07% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 18.0M -50.43% | 36.3M +38.22% | 26.3M -14.59% | 30.8M -71.84% | |
Short-Term Investments | 73.5M -14.87% | 86.3M -13.46% | 99.7M -14.14% | 116.1M +152.28% | |
Cash and Cash Equivalents and Short-Term Investments | 91.5M -25.40% | 122.6M -2.68% | 126.0M -14.23% | 146.9M -5.41% | |
Total Current Assets | 94.5M -25.81% | 127.3M -3.57% | 132.0M -12.65% | 151.1M -5.93% | |
Accumulated Depreciation | 0 -100.00% | 6.1M -48.70% | 11.9M +10.17% | 10.8M +15.22% | |
Property and Plant and Equipment and Net | 32,000 -99.03% | 3.3M -29.20% | 4.7M -7.81% | 5.1M -15.26% | |
Total Long-Term Assets | 130,000 +282.35% | 34,000 N/A | 0 -100.00% | 103,000 +68.85% | |
Total Assets | 94.6M -28.16% | 131.7M -8.79% | 144.4M -26.11% | 195.4M -4.43% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 6.0M -61.54% | 15.6M -30.55% | 22.5M -31.56% | 32.9M +192.82% | |
Total Long-Term Debt | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Long-Term Liabilities | 199,000 -94.58% | 3.7M +173.19% | 1.3M -82.81% | 7.8M +250.25% | |
Total Liabilities | 18.0M -47.46% | 34.3M -10.53% | 38.4M -34.46% | 58.6M +67.11% | |
Retained Earnings | -1.4B +2.49% | -1.3B +5.48% | -1.3B +6.05% | -1.2B +6.12% | |
Total Stockholders Equity | 76.6M -21.35% | 97.4M -8.16% | 106.0M -22.53% | 136.9M -19.23% | |
Total Shares Outstanding | 192.5M +1.35% | 190.0M +11.83% | 169.9M +7.88% | 157.5M +8.60% | |
Cash Flow | |||||
Cash from Operating Activities | -39.6M -38.88% | -64.8M -24.54% | -85.9M +143.06% | -35.4M -47.65% | |
Capital Expenditures | 0 -100.00% | 182,000 -81.94% | 1.0M +96.88% | 512,000 -36.71% | |
Cash from Investing Activities | 15.6M -32.11% | 22.9M -54.80% | 50.8M +167.75% | -74.9M +491.12% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 5.7M -89.00% | 52.0M +69.66% | 30.6M -3.67% | 31.8M -76.82% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -302.83% -84.45% | -1,947.41% +352.33% | -430.53% +156.65% | -167.75% -74.93% | |
Return on Assets | -29.60% -41.55% | -50.65% +18.13% | -42.88% +23.43% | -34.74% -22.20% | |
Return on Equity | -38.52% -43.98% | -68.76% +14.61% | -59.99% +32.27% | -45.35% -19.28% | |
Revenue Growth | 221.54% +382.58% | -78.40% +46.52% | -53.51% -120.97% | 255.11% +332.94% | |
Current Ratio | 15.73 +92.92% | 8.15 +38.84% | 5.87 +27.64% | 4.60 -67.87% | |
Cash Ratio | 3.00 +28.89% | 2.33 +99.01% | 1.17 +24.79% | 0.94 -90.38% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow